Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Dana consortium on HIV dementia begins with study of Otsuka's OPC-14117.

  • News

Executive Summary

DANA HIV DEMENTIA CONSORTIUM STUDYING OTSUKA's OPC-14117 in the first trial to be undertaken by the Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. The initial trial uses Otsuka Pharmaceutical's OPC-14117 under an IND held by investigator Karl Kieburtz, MD, University of Rochester. Otsuka is donating drug and placebo and allowed cross referencing of its DMF and IND; the agreement is not licensure and Otsuka retains rights to further development.

Table

View full table

Tags:
Latest Headlines

Shionogi: Other Countries Must Follow UK’s Lead On Antimicrobial Incentives

Industry Calls For Caution Over EMA Supply Chain Recommendations

Industry Slates Decision To Exempt Parallel Importers From New Danish Stockpile Rules

Asian Industry Groups Push For Universal Care, E-Labeling, Flexible Supply Chain

See All
UsernamePublicRestriction

Register

PS025682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By